Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment

TL;DR: The latest findings on the numerous effects of microbiota on carcinogenesis, ranging from promoting, preventing, or even influencing therapeutic outcomes, are discussed and potential mechanisms by which the microbiota mediates such a wide impact are highlighted.

TL;DR: The role and potential molecular biological mechanisms of ZEB1‐AS1 in colon adenocarcinoma (COAD) are identified and the potential mechanisms behind the oncogenic regulator role are identified.

TL;DR: Mechanisms by which microbiota may impact systemic and antitumor immunity, in addition to outstanding questions in the field are discussed.

TL;DR: It is suggested that targeting F. nucleatum, during chemotherapy, could result in variable therapeutic outcomes for ESCC patients, as the mechanism underlying chemotherapeutic resistance is uncovered.

TL;DR: It is proposed that the metabolism of cancer cells, and indeed all proliferating cells, is adapted to facilitate the uptake and incorporation of nutrients into the biomass needed to produce a new cell.

TL;DR: The Human Microbiome Project Consortium reported the first results of their analysis of microbial communities from distinct, clinically relevant body habitats in a human cohort; the insights into the microbial communities of a healthy population lay foundations for future exploration of the epidemiology, ecology and translational applications of the human microbiome as discussed by the authors.

TL;DR: Integrative analyses suggest new markers for aggressive colorectal carcinoma and an important role for MYC-directed transcriptional activation and repression.

TL;DR: The origin, mechanisms of expansion and suppressive functions of MDSCs, as well as the potential to target these cells for therapeutic benefit are discussed.